Discover how breast cancer precision oncology using a combination therapy improves survival in advanced PIK3CA-mutated cases.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive final results from the overall ...

A “breakthrough” new three-drug combination offers hope for women battling an aggressive form of breast cancer, potentially ...

INAVO120 trial shows inavolisib, palbociclib, and fulvestrant significantly improved overall survival in PIK3CA-mutant ...

Final OS results from INAVO120 show inavolisib plus palbociclib and fulvestrant significantly improves survival, delays ...

A new triple therapy for aggressive, advanced breast cancer slows the progression of the disease, delays the need for further chemotherapy and helps patients live longer, research revealed.The ...

The phase 3 PADMA trial demonstrated that first-line treatment with palbociclib plus endocrine therapy (ET) significantly improves outcomes compared with standard mono chemotherapy in patients ...

A new triple-drug treatment for aggressive advanced breast cancer can cut deaths by a third, a major trial has found.

The lead author said the study also showed the inavolisib-based therapy "more than doubled the time before their cancer progressed or worsened".

The addition of palbociclib to anti-HER2 and endocrine therapy extended PFS by more than a year. The regimen appeared well tolerated, according to investigators. Perspective from Antoinette R.

The Itovebi (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer, compared with palbociclib and ...